Evaluation of the effect of metformin in STEMI patients treated with thrombolytic therapy

Evaluation of the effect of metformin on cardiac troponin-I in STEMI patients treated with thrombolytic therapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20111206008307N34

Enrollment

Registered

2020-06-02

Start date

2020-01-05

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic heart diseases patients. ischemic heart diseases

Interventions

Intervention 1: Intervention group: intervention group will recieve 1000 mg of metformin before thrombolytic with standard treatments. Intervention 2: Control group:Control group will only recieve sta

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Ischemic heart diseases age 18-80 undergoing of thrombolytic therapy filling of consent form

Exclusion criteria

Exclusion criteria: Elevation of troponin I- (above normal) at least 48 hours before thrombolytic therapy history of CABG during last three months history of previous MI; renal failure (creatinine clearance below 30 mg / dl or creatinine above 1 /4 in women and 1/5 in men) sensitivity to aspirin or clopidogrel and retaplase cardiogenic shock; history of end-stage renal failure or dialysis presence of metformin inhibition

Design outcomes

Primary

Measure	Time frame
CTnI level. Timepoint: BASELINE?8?16? 24 AND 32 HOURS AFTER Thrombolytic. Method of measurement: ELISA.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Taher Entezari-Maleki

Tabriz University of Medical Sciences

tentezari@gmail.com+98 41 1339 2593

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026